Inhibition DDIs with AUC ratios ≥5, NME as inhibitor
Drugs were orally administered.
| Victim Drug | Inhibitor | Main Enzymes/Transporters Possibly Involved | AUC Ratio | Reference |
|---|---|---|---|---|
| Tacrolimus | Ombitasvir, paritaprevir, and ritonavir | CYP3A, P-gp | 85.92 | FDA (2014m) |
| Tacrolimus | Paritaprevir, dasabuvir, and ritonavir | CYP3A, P-gp | 78.68 | FDA (2014m) |
| Tacrolimus | Ombitasvir, paritaprevir, dasabuvir, and ritonavir | CYP3A, P-gp | 57.07 | FDA (2014m) |
| Cyclosporine | Ombitasvir, paritaprevir, dasabuvir, and ritonavir | CYP3A, P-gp | 5.78 | FDA (2014m) |
| Midazolam | Idelalisib | CYP3A | 5.15 | FDA (2014o) |